Xixi Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xixi Liu has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Chao Wan
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
14 shared publications - Fang Huang
Huazhong University of Science and Technology 1 Cancer Center, Union Hospital, Tongji Medical College Wuhan, China
14 shared publications - Jiacheng Wang
Huazhong University of Science and Technology 1 Cancer Center, Union Hospital, Tongji Medical College Wuhan, China
14 shared publications - Jingshu Meng
Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China
14 shared publications - Kunyu Yang
Huazhong University of Science and Technology 1 Cancer Center, Union Hospital, Tongji Medical College Wuhan, China
14 shared publications - Lingyi Kong
Huazhong University of Science and Technology 1 Cancer Center, Union Hospital, Tongji Medical College Wuhan, China
14 shared publications
Latest Publications
Postoperative anlotinib plus radiotherapy in patients with newly diagnosed, unmethylated O 6 ‐methylguanine–DNA methyltransferase glioblastoma: A single‐arm, phase 2 study
Background: Patients with unmethylated O 6 ‐methylguanine–DNA methyltransferase ( MGMT ) glioblastoma derive minimal benefit from the standard temozolomide chemoradiotherapy, leaving an urgent need for more effective therapies. The objective of this phase 2 study was to evaluate the efficacy of anlotinib plus radiotherapy in this disease. Methods: In this single‐arm, phase 2 study, patients with newly diagnosed, unmethylated MGMT glioblastoma were recruited after surgical resection. Patients received standard radiotherapy (60.0 grays) and concomitant with anlotinib (12 mg once daily, 2 weeks on/1 week off), followed by six cycles of anlotinib maintenance. The primary end point was overall survival (OS). Secondary end points were progression‐free survival (PFS), OS rates at 12 and 24 months, PFS rates at 6 and 12 months, and safety. Results: Between October 12, 2020, and August 1, 2022, 32 patients were enrolled and received protocol therapy, and all were evaluable for efficacy and safety analyses. At a median follow‐up of 18.6 months (range, 8.3–50.3 months), the median OS was 19.1 months (95% confidence interval, 14.4–22.4 months), with 12‐month and 24‐month OS rates of 90.6% and 30.0%, respectively. The median OS did not reach the prespecified threshold of 20.1 months. The median PFS was 11.1 months (95% confidence interval, 9.6–12.9 months), with 6‐month and 12‐month PFS rates of 96.9% and 37.5%, respectively. Four patients (12.5%) experienced grade 3 or worse treatment‐related adverse events, two of which (6.3%) were serious. No treatment‐related deaths occurred. Conclusions: Postoperative anlotinib plus radiotherapy demonstrated clinically meaningful activity with a manageable safety profile in patients with unmethylated MGMT glioblastoma (Chinese Clinical Trials Registry identifier: ChiCTR2000040116).
Postoperative anlotinib plus radiotherapy in patients with newly diagnosed, unmethylated O 6 ‐methylguanine–DNA methyltransferase glioblastoma: A single‐arm, phase 2 study
Background: Patients with unmethylated O 6 ‐methylguanine–DNA methyltransferase ( MGMT ) glioblastoma derive minimal benefit from the standard temozolomide chemoradiotherapy, leaving an urgent need for more effective therapies. The objective of this phase 2 study was to evaluate the efficacy of anlotinib plus radiotherapy in this disease. Methods: In this single‐arm, phase 2 study, patients with newly diagnosed, unmethylated MGMT glioblastoma were recruited after surgical resection. Patients received standard radiotherapy (60.0 grays) and concomitant with anlotinib (12 mg once daily, 2 weeks on/1 week off), followed by six cycles of anlotinib maintenance. The primary end point was overall survival (OS). Secondary end points were progression‐free survival (PFS), OS rates at 12 and 24 months, PFS rates at 6 and 12 months, and safety. Results: Between October 12, 2020, and August 1, 2022, 32 patients were enrolled and received protocol therapy, and all were evaluable for efficacy and safety analyses. At a median follow‐up of 18.6 months (range, 8.3–50.3 months), the median OS was 19.1 months (95% confidence interval, 14.4–22.4 months), with 12‐month and 24‐month OS rates of 90.6% and 30.0%, respectively. The median OS did not reach the prespecified threshold of 20.1 months. The median PFS was 11.1 months (95% confidence interval, 9.6–12.9 months), with 6‐month and 12‐month PFS rates of 96.9% and 37.5%, respectively. Four patients (12.5%) experienced grade 3 or worse treatment‐related adverse events, two of which (6.3%) were serious. No treatment‐related deaths occurred. Conclusions: Postoperative anlotinib plus radiotherapy demonstrated clinically meaningful activity with a manageable safety profile in patients with unmethylated MGMT glioblastoma (Chinese Clinical Trials Registry identifier: ChiCTR2000040116).
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S11 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Targeting CD24 does not sensitize radiotherapy in vitro.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S11 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Targeting CD24 does not sensitize radiotherapy in vitro.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S13 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Validation of the immune cell depletion efficiency, related to Fig. 7.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S13 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Validation of the immune cell depletion efficiency, related to Fig. 7.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S6 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation suppresses APC/C-mediated ubiquitination of GPAA1.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S6 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation suppresses APC/C-mediated ubiquitination of GPAA1.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation enhances GPAA1 to promote CD24 membrane trafficking.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation enhances GPAA1 to promote CD24 membrane trafficking.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S8 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation mediates GPAA1 accumulation via APC/C disruption.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S8 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation mediates GPAA1 accumulation via APC/C disruption.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S10 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
GPAA1 inhibition combined with radiation promotes macrophage uptake and abolished by CD24 overexpression.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S10 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
GPAA1 inhibition combined with radiation promotes macrophage uptake and abolished by CD24 overexpression.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S12 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
CD24-radiation combination therapy activates macrophages and T cells.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S12 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
CD24-radiation combination therapy activates macrophages and T cells.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
CD24 ablation combined with radiation promotes macrophages uptake.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
CD24 ablation combined with radiation promotes macrophages uptake.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation enhances ‘don’t eat me’ signal CD24 on tumor cells.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion
Radiation enhances ‘don’t eat me’ signal CD24 on tumor cells.